Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NFM4

UPID:
ADCY4_HUMAN

ALTERNATIVE NAMES:
ATP pyrophosphate-lyase 4; Adenylate cyclase type IV; Adenylyl cyclase 4

ALTERNATIVE UPACC:
Q8NFM4; B3KV74; D3DS75; Q17R40; Q6ZTM6; Q96ML7

BACKGROUND:
Adenylate cyclase type 4, with alternative names such as ATP pyrophosphate-lyase 4 and Adenylyl cyclase 4, is essential for cAMP production following G-protein signaling. This enzyme's activity is fundamental for the proper transmission of external signals into cellular responses, influencing a wide range of biological functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Adenylate cyclase type 4 holds promise for identifying novel therapeutic approaches. Given its crucial role in signal transduction mechanisms, targeting this protein could lead to innovative treatments by manipulating cAMP signaling pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.